{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:10:10Z","timestamp":1791897010639,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Roma La Sapienza"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We assessed the clinical effectiveness of cefiderocol (CFDC) in comparison with colistin (COL) for the treatment of carbapenem-resistant <jats:italic>Acinetobacter baumannii<\/jats:italic> (CRAB) bloodstream infections (BSI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials\/methods<\/jats:title>\n                <jats:p>Retrospective cohort study including adults with CRAB-BSI. Outcomes were mortality, clinical cure and adverse events during therapy. The average treatment effect of CFDC compared to COL was weighted with the inverse-probability treatment weight (IPTW).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 104 patients were included (50 CFDC, 54 COL), median age 66.5 years, median Charlson Comorbidity Index 5, septic shock in 33.6% of patients. Primary BSI accounted for 43.3% of cases, followed by ventilator-associated pneumonia (VAP) (26%), catheter-related BSI (20.2%) and hospital-acquired pneumonia (HAP) (9.6%). Although not significantly, mortality at all time points was lower for CFDC than COL, while clinical cure was higher in CFDC than COL (66% vs. 44.4%, <jats:italic>p<\/jats:italic>\u2009=\u20090.027). Adverse events were more frequent in COL than CFDC-group (38.8% vs. 10%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), primarily attributed to acute kidney injury (AKI) in the COL group. Patients with bacteremic HAP\/VAP treated with CFDC had a significant lower 30-d mortality and higher clinical cure than COL (<jats:italic>p<\/jats:italic>\u2009=\u20090.008 and <jats:italic>p<\/jats:italic>\u2009=\u20090.0008, respectively). Increment of CCI (<jats:italic>p<\/jats:italic>\u2009=\u20090.005), ICU (<jats:italic>p<\/jats:italic>\u2009=\u20090.025), SARS-CoV2 (<jats:italic>p<\/jats:italic>\u2009=\u20090.006) and ECMO (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) were independently associated with 30-d mortality, while receiving CFDC was not associated with survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>CFDC could represent an effective and safe treatment option for CRAB BSI, especially in patients with bacteremic HAP\/VAP and frail patients where the risk of acute renal failure during therapy should be avoided.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10096-024-04833-8","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T10:20:22Z","timestamp":1713435622000},"page":"1149-1160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0832-7975","authenticated-orcid":false,"given":"Alessandra","family":"Oliva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Covino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Cogliati-Dezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Curtolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Savelloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Viscido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Alessandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Raponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CM","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"4833_CR1","unstructured":"Newsroom Antibiotic resistance. World Health Organization [cited 2023 July 23]. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antibiotic-resistance"},{"issue":"3","key":"4833_CR2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A et al (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18(3):318\u2013327. https:\/\/doi.org\/10.1016\/S1473-3099(17)30753-3Epub 2017 Dec 21. PMID: 29276051","journal-title":"Lancet Infect Dis"},{"key":"4833_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-020-00750-5","author":"O Ayobami","year":"2020","unstructured":"Ayobami O, Willrich N, Suwono B, Eckmanns T, Markwart R (2020) The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe. Antimicrob Resist Infect Control 9(1):89. https:\/\/doi.org\/10.1186\/s13756-020-00750-5PMID: 32560670; PMCID: PMC7304165 : analysis of EARS-Net data from 2013 to 2017"},{"issue":"2","key":"4833_CR4","doi-asserted-by":"publisher","first-page":"e0275921","DOI":"10.1128\/mbio.02759-21","volume":"13","author":"A Iovleva","year":"2022","unstructured":"Iovleva A, Mustapha MM, Griffith MP et al (2022) Carbapenem-Resistant Acinetobacter baumannii in U.S. hospitals: diversification of circulating lineages and Antimicrobial Resistance. mBio 13(2):e0275921. https:\/\/doi.org\/10.1128\/mbio.02759-21Epub 2022 Mar 21. PMID: 35311529; PMCID: PMC9040734","journal-title":"mBio"},{"key":"4833_CR5","doi-asserted-by":"publisher","first-page":"1196774","DOI":"10.3389\/fmicb.2023.1196774","volume":"14","author":"I Cavallo","year":"2023","unstructured":"Cavallo I, Oliva A, Pages R et al (2023) Acinetobacter baumannii in the critically ill: complex infections get complicated. Front Microbiol 14:1196774. https:\/\/doi.org\/10.3389\/fmicb.2023.1196774PMID: 37425994; PMCID: PMC10325864","journal-title":"Front Microbiol"},{"key":"4833_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jgar.2019.06.009","volume":"20","author":"DR Giacobbe","year":"2020","unstructured":"Giacobbe DR, Saffioti C, Losito AR et al (2020) Use of colistin in adult patients: a cross-sectional study. J Glob Antimicrob Resist 20:43\u201349. https:\/\/doi.org\/10.1016\/j.jgar.2019.06.009Epub 2019 Jun 15. PMID: 31207379","journal-title":"J Glob Antimicrob Resist"},{"issue":"6","key":"4833_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1378\/chest.10-0463","volume":"138","author":"R Imberti","year":"2010","unstructured":"Imberti R, Cusato M, Villani P et al (2010) Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 138(6):1333\u20131339. https:\/\/doi.org\/10.1378\/chest.10-0463Epub 2010 Jun 17. PMID: 20558557","journal-title":"Chest"},{"issue":"7","key":"4833_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00228-015-1865-4","volume":"71","author":"A Ordooei Javan","year":"2015","unstructured":"Ordooei Javan A, Shokouhi S, Sahraei Z (2015) A review on colistin nephrotoxicity. Eur J Clin Pharmacol 71(7):801\u2013810. https:\/\/doi.org\/10.1007\/s00228-015-1865-4Epub 2015 May 27. PMID: 26008213","journal-title":"Eur J Clin Pharmacol"},{"key":"4833_CR9","doi-asserted-by":"publisher","first-page":"17091","DOI":"10.1038\/srep17091","volume":"5","author":"Z Chen","year":"2015","unstructured":"Chen Z, Chen Y, Fang Y et al (2015) Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Sci Rep 5:17091. https:\/\/doi.org\/10.1038\/srep17091PMID: 26597507; PMCID: PMC4657015","journal-title":"Sci Rep"},{"key":"4833_CR10","doi-asserted-by":"publisher","unstructured":"Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N (2018) Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother. ;73(1):22\u201332. https:\/\/doi.org\/10.1093\/jac\/dkx368. PMID: 29069421","DOI":"10.1093\/jac\/dkx368"},{"issue":"7","key":"4833_CR11","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/jac\/dks084","volume":"67","author":"Y Cai","year":"2012","unstructured":"Cai Y, Chai D, Wang R, Liang B, Bai N (2012) Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67(7):1607\u20131615. https:\/\/doi.org\/10.1093\/jac\/dks084Epub 2012 Mar 22. PMID: 22441575","journal-title":"J Antimicrob Chemother"},{"key":"4833_CR12","unstructured":"US Food and Drug Administration (2019) Highlights of prescribing information: Fetroja (Cefiderocol). [cited 2023 July 23]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/209445s000lbl.pdf"},{"issue":"2","key":"4833_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226\u2013240. https:\/\/doi.org\/10.1016\/S1473-3099(20)30796-9Epub 2020 Oct 12. PMID: 33058795","journal-title":"Lancet Infect Dis"},{"key":"4833_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jgar.2020.09.019","volume":"23","author":"A Oliva","year":"2020","unstructured":"Oliva A, Ceccarelli G, De Angelis M et al (2020) Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii. J Glob Antimicrob Resist 23:292\u2013296 Epub 2020 Oct 13. PMID: 33065329","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"4833_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/antibiotics11010003","volume":"11","author":"E Rando","year":"2021","unstructured":"Rando E, Segala FV, Vargas J et al (2021) Cefiderocol for severe carbapenem-resistant A. Baumannii Pneumonia: towards the comprehension of its place in Therapy. Antibiot (Basel) 11(1):3. https:\/\/doi.org\/10.3390\/antibiotics11010003PMID: 35052880; PMCID: PMC8773286","journal-title":"Antibiot (Basel)"},{"issue":"6","key":"4833_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/antibiotics10060652","volume":"10","author":"DF Bavaro","year":"2021","unstructured":"Bavaro DF, Belati A, Diella L et al (2021) Cefiderocol-based combination therapy for difficult-to-treat Gram-negative severe infections: real-life Case Series and Future perspectives. Antibiot (Basel) 10(6):652. https:\/\/doi.org\/10.3390\/antibiotics10060652PMID: 34072342; PMCID: PMC8227820","journal-title":"Antibiot (Basel)"},{"issue":"6","key":"4833_CR17","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/antibiotics12061048","volume":"12","author":"L Dalfino","year":"2023","unstructured":"Dalfino L, Stufano M, Bavaro DF et al (2023) Effectiveness of First-Line therapy with Old and Novel antibiotics in Ventilator-Associated Pneumonia caused by Carbapenem-Resistant Acinetobacter baumannii: a real life, prospective, observational, single-center study. Antibiot (Basel) 12(6):1048. https:\/\/doi.org\/10.3390\/antibiotics12061048PMID: 37370367; PMCID: PMC10295543","journal-title":"Antibiot (Basel)"},{"issue":"4","key":"4833_CR18","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/microorganisms11040984","volume":"11","author":"M Mazzitelli","year":"2023","unstructured":"Mazzitelli M, Gregori D, Sasset L et al (2023) Cefiderocol-based versus colistin-based regimens for severe carbapenem-resistant Acinetobacter baumannii infections: a propensity Score-Weighted, Retrospective Cohort Study during the first two years of the COVID-19 pandemic. Microorganisms 11(4):984. https:\/\/doi.org\/10.3390\/microorganisms11040984PMID: 37110408; PMCID: PMC10146662","journal-title":"Microorganisms"},{"key":"4833_CR19","doi-asserted-by":"publisher","unstructured":"Falcone M, Tiseo G, Nicastro M et al (2021) Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients. Clin Infect Dis. ;72(11):2021\u20132024. https:\/\/doi.org\/10.1093\/cid\/ciaa1410. PMID: 32941593","DOI":"10.1093\/cid\/ciaa1410"},{"issue":"1","key":"4833_CR20","doi-asserted-by":"publisher","first-page":"106825","DOI":"10.1016\/j.ijantimicag.2023.106825","volume":"62","author":"A Russo","year":"2023","unstructured":"Russo A, Bruni A, Gull\u00ec S et al (2023) Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents 62(1):106825. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106825Epub 2023 Apr 21. PMID: 37088438; PMCID: PMC10121149","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"4833_CR21","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1007\/s40121-023-00854-6","volume":"12","author":"DF Bavaro","year":"2023","unstructured":"Bavaro DF, Papagni R, Belati A, Diella L, De Luca A, Brindicci G, De Gennaro N, Di Gennaro F, Romanelli F, Stolfa S, Ronga L, Mosca A, Pomarico F, Dell\u2019Aera M, Stufano M, Dalfino L, Grasso S, Saracino A (2023) Cefiderocol Versus Colistin for the treatment of Carbapenem-Resistant Acinetobacter baumannii Complex Bloodstream infections: a retrospective, propensity-score adjusted, Monocentric Cohort Study. Infect Dis Ther 12(8):2147\u20132163. https:\/\/doi.org\/10.1007\/s40121-023-00854-6Epub 2023 Sep 1. PMID: 37653122; PMCID: PMC10505116","journal-title":"Infect Dis Ther"},{"issue":"4","key":"4833_CR22","doi-asserted-by":"publisher","first-page":"dlad085","DOI":"10.1093\/jacamr\/dlad085","volume":"5","author":"E Rando","year":"2023","unstructured":"Rando E, Cutuli SL, Sangiorgi F, Tanzarella ES, Giovannenze F, De Angelis G, Murri R, Antonelli M, Fantoni M, De Pascale G (2023) Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. Baumannii ventilator-associated pneumonia: a propensity-weighted cohort study. JAC Antimicrob Resist 5(4):dlad085. https:\/\/doi.org\/10.1093\/jacamr\/dlad085PMID: 37484029; PMCID: PMC10359102","journal-title":"JAC Antimicrob Resist"},{"issue":"5","key":"4833_CR23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"4833_CR24","unstructured":"CDC\/NHSN Surveillance Definitions for Specific Types of Infections [retrieved October 2022]. https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/17pscnosinfdef_current.pdf"},{"key":"4833_CR25","unstructured":"Centers for Disease Control and Prevention website. National Healthcare safety Network (NHSN) Pneumonia (Ventilator-associated [VAP] and non-ventilator-associated Pneumonia [PNEU]) Event. [retrieved January 2023]. https:\/\/www.cdc.gov\/nhsn\/pdfs\/pscmanual\/6pscvapcurrent.pdf"},{"issue":"6","key":"4833_CR26","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/infdis\/141.6.781","volume":"141","author":"DJ Cleri","year":"1980","unstructured":"Cleri DJ, Corrado ML, Seligman SJ (1980) Quantitative culture of intravenous catheters and other intravascular inserts. J Infect Dis 141(6):781\u2013786. https:\/\/doi.org\/10.1093\/infdis\/141.6.781","journal-title":"J Infect Dis"},{"key":"4833_CR27","unstructured":"Centers for Disease Control and Prevention website. National Healthcare safety Network (NHSN) Bloodstream Infection (BSI) Events. [cited 2022 January 25]. https:\/\/www.cdc.gov\/nhsn\/psc\/bsi\/index.html"},{"issue":"7","key":"4833_CR28","doi-asserted-by":"publisher","first-page":"ofad327","DOI":"10.1093\/ofid\/ofad327","volume":"10","author":"A Oliva","year":"2023","unstructured":"Oliva A, Campogiani L, Savelloni G et al (2023) Clinical characteristics and outcome of Ceftazidime\/Avibactam-Resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae infections: a retrospective, observational, 2-Center Clinical Study. Open Forum Infect Dis 10(7):ofad327. https:\/\/doi.org\/10.1093\/ofid\/ofad327PMID: 37476077; PMCID: PMC10354859","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"4833_CR29","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1186\/cc5713","volume":"11","author":"RL Mehta","year":"2007","unstructured":"Mehta RL, Kellum JA, Shah SV et al (2007) Acute kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11(2):R31. https:\/\/doi.org\/10.1186\/cc5713PMID: 17331245; PMCID: PMC2206446","journal-title":"Crit Care"},{"issue":"1","key":"4833_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum JA, Lameire N, KDIGO AKI Guideline Work Group (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care 17(1):204. https:\/\/doi.org\/10.1186\/cc11454PMID: 23394211; PMCID: PMC4057151","journal-title":"Crit Care"},{"key":"4833_CR31","unstructured":"EUCAST European Committe on antimicrobial susceptibility testing Website. Clinical breakpoints - breakpoints and guidance January 2 (2023) Clinical breakpoints (v 13.1) - new file for printing (29 June, 2023) to make new breakpoints for anaerobic bacteria available. [cited 2023 July 21]. https:\/\/www.eucast.org\/clinical_breakpoints"},{"key":"4833_CR32","doi-asserted-by":"crossref","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ Infectious Diseases Society of America Antimicrobial-Resistant Treatment Guidance: Gram-Negative Bacterial Infections. Infectious Diseases Society of America 2023; Version 3.0. [cited 2023 June 18]. https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/","DOI":"10.1093\/cid\/ciad428"},{"key":"4833_CR33","doi-asserted-by":"publisher","unstructured":"Tiseo G, Brigante G, Giacobbe DR et al (2022) Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). Int J Antimicrob Agents. ;60(2):106611. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106611. Epub 2022 Jun 11. PMID: 35697179","DOI":"10.1016\/j.ijantimicag.2022.106611"},{"issue":"4","key":"4833_CR34","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P et al (2022) European Society of Clinical Microbiology and Infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 28(4):521\u2013547 Epub 2021 Dec 16. PMID: 34923128","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"4833_CR35","doi-asserted-by":"publisher","first-page":"dlab174","DOI":"10.1093\/jacamr\/dlab174","volume":"3","author":"R Pascale","year":"2021","unstructured":"Pascale R, Pasquini Z, Bartoletti M et al (2021) Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC Antimicrob Resist 3(4):dlab174. https:\/\/doi.org\/10.1093\/jacamr\/dlab174PMID: 34806011; PMCID: PMC8599913","journal-title":"JAC Antimicrob Resist"},{"key":"4833_CR36","doi-asserted-by":"crossref","unstructured":"Gatti M, Cosentino F, Giannella M, Viale P, Pea F (2023) Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis. Int J Antimicrob Agents. ;63(2):107047. doi: 10.1016\/j.ijantimicag.2023.107047. Epub ahead of print. PMID: 38061418","DOI":"10.1016\/j.ijantimicag.2023.107047"},{"key":"4833_CR37","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1093\/jac\/dkab280","volume":"76","author":"T Katsube","year":"2021","unstructured":"Katsube T, Nicolau DP, Rodvold KA et al (2021) Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. J Antimicrob Chemother 76:2902\u20132905","journal-title":"J Antimicrob Chemother"},{"key":"4833_CR38","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jgar.2021.10.014","volume":"27","author":"M Gatti","year":"2021","unstructured":"Gatti M, Bartoletti M, Cojutti PG et al (2021) A descriptive case series of pharmacokinetic\/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and\/or ventilator-associated pneumonia treated with cefiderocol. J Glob Antimicrob Resist 27:294\u2013298 Epub 2021 Oct 26. PMID: 34710630","journal-title":"J Glob Antimicrob Resist"},{"key":"4833_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s15010-021-01643-4","volume":"50","author":"A Russo","year":"2022","unstructured":"Russo A, Gavaruzzi F, Ceccarelli G et al (2022) Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit. Infection 50:83\u201392","journal-title":"Infection"},{"issue":"7","key":"4833_CR40","doi-asserted-by":"publisher","first-page":"926","DOI":"10.3390\/antibiotics11070926","volume":"11","author":"F Cogliati Dezza","year":"2022","unstructured":"Cogliati Dezza F, Arcari G, Alessi F et al (2022) Clinical impact of COVID-19 on Multi-drug-resistant Gram-negative Bacilli Bloodstream infections in an intensive care unit setting: two pandemics compared. Antibiot (Basel) 11(7):926. https:\/\/doi.org\/10.3390\/antibiotics11070926PMID: 35884179; PMCID: PMC9312122","journal-title":"Antibiot (Basel)"},{"issue":"6","key":"4833_CR41","doi-asserted-by":"publisher","first-page":"dlac121","DOI":"10.1093\/jacamr\/dlac121","volume":"4","author":"A Oliva","year":"2022","unstructured":"Oliva A, Volpicelli L, Di Bari S et al (2022) Effect of ceftazidime\/avibactam plus fosfomycin combination on 30\u00a0day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study. JAC Antimicrob Resist 4(6):dlac121. https:\/\/doi.org\/10.1093\/jacamr\/dlac121PMID: 36506890; PMCID: PMC9728520","journal-title":"JAC Antimicrob Resist"},{"key":"4833_CR42","doi-asserted-by":"publisher","unstructured":"Dhamija A, Thibault D, Fugett J et al (2022) Incremental effect of complications on mortality and hospital costs in adult ECMO patients. Perfusion. ;37(5):461\u2013469. https:\/\/doi.org\/10.1177\/02676591211005697. Epub 2021 Mar 26. PMID: 33765884","DOI":"10.1177\/02676591211005697"},{"issue":"1","key":"4833_CR43","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1186\/s13054-020-03397-1","volume":"24","author":"D K\u00fchn","year":"2020","unstructured":"K\u00fchn D, Metz C, Seiler F et al (2020) Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study. Crit Care 24(1):664. https:\/\/doi.org\/10.1186\/s13054-020-03397-1PMID: 33239110; PMCID: PMC7689974","journal-title":"Crit Care"},{"key":"4833_CR44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ajem.2022.08.003","volume":"60","author":"R Jouffroy","year":"2022","unstructured":"Jouffroy R, Parfait PA, Gilbert B et al (2022) Relationship between prehospital modified Charlson Comorbidity Index and septic shock 30-day mortality. Am J Emerg Med 60:128\u2013133 Epub 2022 Aug 6. PMID: 35961123","journal-title":"Am J Emerg Med"},{"key":"4833_CR45","doi-asserted-by":"publisher","unstructured":"Cogliati Dezza F, Covino S, Petrucci F et al (2023) Risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and related mortality in critically ill patients with CRAB colonization. JAC Antimicrob Resist 5(4):dlad096. https:\/\/doi.org\/10.1093\/jacamr\/dlad096","DOI":"10.1093\/jacamr\/dlad096"},{"issue":"3","key":"4833_CR46","doi-asserted-by":"publisher","first-page":"dlaa060","DOI":"10.1093\/jacamr\/dlaa060","volume":"2","author":"SIDERO Longshaw","year":"2020","unstructured":"Longshaw SIDERO, Manissero C, Tsuji D, Echols M, Yamano R (2020) In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible gram-negative bacteria from Europe. JAC Antimicrob Resist 2(3):dlaa060. https:\/\/doi.org\/10.1093\/jacamr\/dlaa060PMID: 34223017; PMCID: PMC8210120","journal-title":"JAC Antimicrob Resist"},{"issue":"12","key":"4833_CR47","doi-asserted-by":"publisher","first-page":"e01582","DOI":"10.1128\/AAC.01582-20","volume":"64","author":"S Mushtaq","year":"2020","unstructured":"Mushtaq S, Sadouki Z, Vickers A, Livermore DM, Woodford N (2020) Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-negative Bacteria. Antimicrob Agents Chemother 64(12):e01582\u2013e01520. https:\/\/doi.org\/10.1128\/AAC.01582-20PMID: 32958717; PMCID: PMC767404","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"4833_CR48","doi-asserted-by":"publisher","first-page":"261","DOI":"10.21037\/atm-22-889","volume":"10","author":"Y Wang","year":"2022","unstructured":"Wang Y, Li Y, Zhao J, Guan J, Ni W, Gao Z (2022) Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria. Ann Transl Med 10(5):261. https:\/\/doi.org\/10.21037\/atm-22-889PMID: 35402576; PMCID: PMC8987888","journal-title":"Ann Transl Med"},{"issue":"6","key":"4833_CR49","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/antibiotics11060723","volume":"11","author":"S Karakonstantis","year":"2022","unstructured":"Karakonstantis S, Rousaki M, Kritsotakis EI, Cefiderocol (2022) Systematic review of mechanisms of Resistance, Heteroresistance and in vivo emergence of resistance. Antibiot (Basel) 11(6):723. https:\/\/doi.org\/10.3390\/antibiotics11060723PMID: 35740130; PMCID: PMC9220290","journal-title":"Antibiot (Basel)"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04833-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-024-04833-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04833-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T14:11:20Z","timestamp":1718374280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-024-04833-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["4833"],"URL":"https:\/\/doi.org\/10.1007\/s10096-024-04833-8","relation":{"references":[{"id-type":"uri","id":"","asserted-by":"subject"}]},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"8 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OA participated to advisory boards or speaker\u2019s bureau for MSD, Zambon and Angelini. VM participated to advisory boards or speaker\u2019s bureau for Gilead, MSD and Mundipharma. MCM participated to advisory boards or speaker\u2019s bureau for Gilead, ASTRA-Zeneca, GSK, and Angelini. Other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the local Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Specific informed consent was waived due to the retrospective nature of the research. Patients (or their representatives) provided consent for use of data for research purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}